Related Experiment Video

Updated: May 13, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma

Sun Min Lim1, Hye Ryun Kim, Hyo Sup Shim

  • 1Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-Gu, Seoul 120-752, Korea.

Future Oncology (London, England)
|March 9, 2013
PubMed

Insights

Fibroblast Growth Factor Receptor 1 (FGFR1) is a promising new target for lung squamous cell carcinoma. Targeting FGFR1 offers new therapeutic options for patients, especially those not benefiting from current treatments.

Area of Science:

  • Oncology
  • Molecular Medicine
  • Genetics

Background:

  • Molecular medicine and high-throughput sequencing have advanced cancer therapeutics.
  • Targetable mutations are often limited to specific cancer subtypes like adenocarcinoma.
  • Existing therapies benefit a narrow patient group, highlighting the need for new targets.

Purpose of the Study:

  • To review the role of Fibroblast Growth Factors (FGFs) and FGF Receptor (FGFR) signaling in cancer.
  • To highlight Fibroblast Growth Factor Receptor 1 (FGFR1) as a novel druggable target in lung squamous cell carcinoma (LUSC).
  • To discuss current therapeutic agents targeting FGFR in clinical development.

Main Methods:

  • Review of existing literature on FGF/FGFR signaling in cancer.
  • Analysis of FGFR1's role in LUSC survival.
  • Survey of ongoing clinical trials for FGFR-targeted therapies.

Main Results:

  • FGFR1 amplification is crucial for the survival of FGFR1-amplified LUSC cell lines.
  • FGFR1 represents a potential therapeutic target in LUSC.
  • Clinical reagents targeting FGFs and FGFRs are under development.

Conclusions:

  • FGFR1 is an emerging therapeutic target for lung squamous cell carcinoma.
  • Targeting FGFR1 may provide new treatment avenues for LUSC patients.
  • Further development of FGFR-targeted agents is warranted for FGFR-dependent cancers.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical, 7TM, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...